Atlas Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $625K | Sell |
10,844
-6,885
| -39% | -$395K | 0.07% | 244 |
|
|
2026
Q1 | $1.08M | Buy |
17,729
+12,860
| +264% | +$750K | 0.12% | 135 |
|
|
2025
Q4 | $263K | Buy |
+4,869
| New | +$234K | 0.03% | 363 |
|
|
2025
Q2 | $351K | Sell |
7,584
-21,702
| -74% | -$1.07M | 0.04% | 308 |
|
|
2025
Q1 | $1.79M | Buy |
29,286
+10,501
| +56% | +$612K | 0.22% | 90 |
|
|
2024
Q4 | $1.06M | Buy |
18,785
+15,585
| +487% | +$871K | 0.13% | 131 |
|
|
2024
Q3 | $166K | Sell |
3,200
-1,600
| -33% | -$75.1K | 0.03% | 406 |
|
|
2024
Q2 | $199K | Buy |
4,800
+1,410
| +42% | +$63.1K | 0.03% | 380 |
|
|
2024
Q1 | $184K | Sell |
3,390
-1,410
| -29% | -$71.8K | 0.03% | 378 |
|
|
2023
Q4 | $246K | Sell |
4,800
-938
| -16% | -$49.2K | 0.04% | 332 |
|
|
2023
Q3 | $333K | Sell |
5,738
-498
| -8% | -$30.5K | 0.05% | 260 |
|
|
2023
Q2 | $399K | Sell |
6,236
-1,005
| -14% | -$67.4K | 0.06% | 244 |
|
|
2023
Q1 | $502K | Sell |
7,241
-580
| -7% | -$40.9K | 0.08% | 193 |
|
|
2022
Q4 | $563K | Buy |
7,821
+124
| +2% | +$9.35K | 0.09% | 173 |
|
|
2022
Q3 | $547K | Sell |
7,697
-1,200
| -13% | -$87K | 0.1% | 171 |
|
|
2022
Q2 | $685K | Buy |
8,897
+1,839
| +26% | +$140K | 0.12% | 149 |
|
|
2022
Q1 | $515K | Sell |
7,058
-68
| -1% | -$4.57K | 0.08% | 212 |
|
|
2021
Q4 | $444K | Sell |
7,126
-3,735
| -34% | -$219K | 0.07% | 232 |
|
|
2021
Q3 | $643K | Sell |
10,861
-961
| -8% | -$63.3K | 0.1% | 169 |
|
|
2021
Q2 | $790K | Buy |
11,822
+726
| +7% | +$47.3K | 0.13% | 140 |
|
|
2021
Q1 | $700K | Sell |
11,096
-9,423
| -46% | -$586K | 0.14% | 150 |
|
|
2020
Q4 | $1.27M | Sell |
20,519
-9,093
| -31% | -$559K | 0.27% | 80 |
|
|
2020
Q3 | $1.79M | Sell |
29,612
-1,541
| -5% | -$92.7K | 0.42% | 51 |
|
|
2020
Q2 | $1.83M | Buy |
31,153
+2,266
| +8% | +$136K | 0.43% | 49 |
|
|
2020
Q1 | $1.54M | Buy |
28,887
+20,846
| +259% | +$1.27M | 0.46% | 47 |
|
|
2019
Q4 | $516K | Buy |
8,041
+1,842
| +30% | +$105K | 0.13% | 194 |
|
|
2019
Q3 | $314K | Sell |
6,199
-645
| -9% | -$30.3K | 0.09% | 256 |
|
|
2019
Q2 | $310K | Buy |
+6,844
| New | +$319K | 0.1% | 234 |
|
|
2019
Q1 | – | Sell |
-1,331
| Closed | -$69.2K | – | 564 |
|
|
2018
Q4 | $69.2K | Hold |
1,331
| – | – | 0.03% | 377 |
|
|
2018
Q3 | $83.4K | Hold |
1,331
| – | – | 0.03% | 375 |
|
|
2018
Q2 | $75.4K | Buy |
+1,331
| New | +$71.9K | 0.03% | 369 |
|
Other funds holding BMY
Atlas Capital Advisors's BMY Position: Q2 2026 in Review
Atlas Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 39% in Q2 2026, selling an estimated $395K and leaving 10,844 shares worth $625K. The position accounts for 0.07% of the portfolio, ranked #244.
Atlas Capital Advisors first reported a position in BMY in Q2 2018 and has held it in 31 quarters since. The position peaked at $1.83M in Q2 2020. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Atlas Capital Advisors held 10,844 shares of Bristol-Myers Squibb worth $625K as of Q2 2026.
- Atlas Capital Advisors sold 6,885 Bristol-Myers Squibb shares in Q2 2026, an estimated $395K.
- Bristol-Myers Squibb made up 0.07% of Atlas Capital Advisors's portfolio in Q2 2026, its #244 holding.
- Atlas Capital Advisors first reported a position in Bristol-Myers Squibb in Q2 2018 and has held it in 31 quarters since.
- Atlas Capital Advisors's Bristol-Myers Squibb position peaked at $1.83M in Q2 2020.
- 2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.